氩氦刀联合艾迪注射液治疗晚期非小细胞肺癌临床观察

Clinical Observation of Argon-Helium Cryoablation Combined with Aidi Injection in Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨氩氦刀局部消融联合艾迪注射液治疗中晚期非小细胞肺癌的疗效及对机体免疫功能的影响。方法36例不能手术或不愿手术的Ⅲ、Ⅳ期非小细胞肺癌患者在CT引导下经皮穿刺氩氦刀局部冷冻消融,术后次日起予艾迪注射液50ml静脉滴注每天一次,连用14天,3周为1周期,连续治疗3周期。结果治疗后肿块CT图像大部分表现为坏死组织。患者KPS评分从治疗前的73.2上升至85.4(P<0.01),咳嗽﹑咯血﹑胸痛和气促的肺癌症状评分(LCSS)从治疗前的65﹑64﹑62和65上升至91﹑88﹑87和90(P<0.01)。T淋巴细胞亚群CD3﹑CD4和CD4/CD8比例及NK细胞水平较治疗前明显增高(P<0.05)。患者1﹑2﹑3年生存率分别为41.6%(15/36),27.7%(10/36)和11.1%(4/36)。结论CT引导下经皮氩氦刀局部消融联合艾迪注射液治疗中晚期非小细胞肺癌可降低肿瘤负荷,改善机体免疫功能,提高病人的生活质量和生存率。

Objective To explore the efficacy and the immunity function of argon-helium cryoablation combined with Aidi injection in treating advanced non-small cell lung cancer. Methods 36 patients with inoperative non-small cell lung cancer were received CT guided percutaneous ar gon-helium cryoablation. From the following day on they were administered Aidi injection 50 ml daily within 14 days, continuously given 3 cycles （3 weeks per cycle）. Results After treatment the tumor tissues were almost of necrosis on CT manifestation. The mean KPS increased from 73,2 at baseline to 84.5 （P 〈0.01）; Lung Cancer Symptom Scale （LCSS） scores of cough, hemoptysis, chest pain and dyspena increased at baseline from 65, 64, 62 and 65 to 91, 88, 87and 90 respectively （P 〈0.01）. The T cell subsets CD3, CD4, CD4/CD5 and NK cell level were significantly higher （P 〈0.05） than those before treatment. The 1-year, 2-year and 3-year survival rates were 41.6% （15/36）, 27.7% （10/36）, and 11.1%（4/36）. Conclusion For the implements of argon-helium cryoablation combined with Aidi injection on advanced non-small cell lung cancer, it can de crease the tumor load, promote the immunity function, improve the patients＇ quality of life and prolong survival.